Lenalidomid Glenmark

Lenalidomide, the active ingredient in Lenalidomid Glenmark, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for systemic use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomid Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomid Glenmark is indicated for hematologic malignancies that respond to immunomodulatory therapy.

Multiple Myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. Myelodysplastic Syndromes (with del(5q)): reduces transfusion dependence and induces cytogenetic remission. Maintenance Therapy in Multiple Myeloma: prolongs remission after initial response.

Lenalidomid Glenmark may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Diarrhea - Constipation - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia or infection risk - Severe thrombocytopenia leading to bleeding - Secondary primary malignancies - Hepatotoxicity - Hypersensitivity reactions including Stevens‑Johnson syndrome

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for known safety concerns.

Pregnancy Contraindication: Lenalidomide is teratogenic; avoid use in pregnant women. Thrombotic Risk: Assess and mitigate risk of blood clots, especially with concomitant steroids. Hematologic Monitoring: Perform regular complete blood counts to detect cytopenias. Renal/Hepatic Function: Adjust therapy based on kidney and liver function assessments. Store at room temperature: keep in the original container, protect from moisture and light.

Lenalidomid Glenmark can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin) can heighten bleeding risk. - Live vaccines: may cause uncontrolled infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) increase gastrointestinal toxicity. - Immunosuppressants may augment infection risk.